CA2377746A1 - N-pyrazole a2a receptor agonists - Google Patents
N-pyrazole a2a receptor agonists Download PDFInfo
- Publication number
- CA2377746A1 CA2377746A1 CA002377746A CA2377746A CA2377746A1 CA 2377746 A1 CA2377746 A1 CA 2377746A1 CA 002377746 A CA002377746 A CA 002377746A CA 2377746 A CA2377746 A CA 2377746A CA 2377746 A1 CA2377746 A1 CA 2377746A1
- Authority
- CA
- Canada
- Prior art keywords
- receptor agonists
- pyrazole
- compounds
- purposes
- adenosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Abstract
2-adenosine N-pyrazole compounds having the following formula:
(see formula I) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilation for therapeutic purposes and for purposes of imaging the heart.
(see formula I) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilation for therapeutic purposes and for purposes of imaging the heart.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/338,185 US6403567B1 (en) | 1999-06-22 | 1999-06-22 | N-pyrazole A2A adenosine receptor agonists |
US09/338,185 | 1999-06-22 | ||
PCT/US2000/040281 WO2000078779A2 (en) | 1999-06-22 | 2000-06-21 | N-pyrazole a2a receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2377746A1 true CA2377746A1 (en) | 2000-12-28 |
CA2377746C CA2377746C (en) | 2007-04-10 |
Family
ID=23323763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002377746A Expired - Lifetime CA2377746C (en) | 1999-06-22 | 2000-06-21 | N-pyrazole a2a receptor agonists |
Country Status (27)
Country | Link |
---|---|
US (9) | US6403567B1 (en) |
EP (1) | EP1189916B1 (en) |
JP (1) | JP4727880B2 (en) |
KR (1) | KR100463300B1 (en) |
CN (1) | CN1167709C (en) |
AR (1) | AR024441A1 (en) |
AT (1) | ATE256141T1 (en) |
AU (1) | AU760806B2 (en) |
BE (1) | BE2011C004I2 (en) |
BR (1) | BRPI0011856B8 (en) |
CA (1) | CA2377746C (en) |
CY (1) | CY2011002I2 (en) |
DE (2) | DE60007127T2 (en) |
DK (1) | DK1189916T3 (en) |
ES (1) | ES2209974T3 (en) |
FR (1) | FR11C0004I2 (en) |
HK (1) | HK1044952B (en) |
IL (2) | IL147198A0 (en) |
LU (1) | LU91785I2 (en) |
MX (1) | MXPA01013325A (en) |
NO (2) | NO322457B1 (en) |
NZ (1) | NZ516334A (en) |
PT (1) | PT1189916E (en) |
TR (1) | TR200200588T2 (en) |
TW (1) | TWI230161B (en) |
WO (1) | WO2000078779A2 (en) |
ZA (1) | ZA200200301B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071566B2 (en) | 2000-02-23 | 2011-12-06 | Gilead Sciences, Inc. | Methods of coronary imaging |
US8106183B2 (en) | 2006-02-03 | 2012-01-31 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
US8133879B2 (en) | 2002-07-29 | 2012-03-13 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
US8183226B2 (en) | 2002-07-29 | 2012-05-22 | Gilead Sciences, Inc. | Myocardial perfusion imaging method |
US8278435B2 (en) | 1999-06-22 | 2012-10-02 | Gilead Sciences, Inc. | N-pyrazole A2A receptor agonists |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US20050059068A1 (en) * | 2001-05-23 | 2005-03-17 | Stratagene California | Compositions and methods using dendrimer-treated microassays |
US7262176B2 (en) | 2001-08-08 | 2007-08-28 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
US20030078232A1 (en) * | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
ES2276084T3 (en) | 2002-02-15 | 2007-06-16 | Cv Therapeutics, Inc. | POLYMER COATING FOR MEDICAL DEVICES. |
US6914053B2 (en) | 2002-09-09 | 2005-07-05 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
JP4818127B2 (en) * | 2004-01-27 | 2011-11-16 | ギリアード・パロ・アルト・インコーポレイテッド | Myocardial perfusion imaging method using adenosine receptor agonist |
TWI346109B (en) * | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
US7423144B2 (en) * | 2004-05-26 | 2008-09-09 | Inotek Pharmaceuticals Corporation | Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof |
ATE531377T1 (en) * | 2004-09-20 | 2011-11-15 | Inotek Pharmaceuticals Corp | PURINE DERIVATIVES AND METHODS OF APPLICATION |
CN101076343A (en) * | 2004-10-20 | 2007-11-21 | Cv医药有限公司 | Use of A2A adenosine receptor agonists |
GT200500281A (en) * | 2004-10-22 | 2006-04-24 | Novartis Ag | ORGANIC COMPOUNDS. |
GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0505219D0 (en) * | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
JP5042996B2 (en) * | 2005-05-19 | 2012-10-03 | ギリアード・パロ・アルト・インコーポレイテッド | A1 adenosine receptor agonist |
BRPI0619261A2 (en) * | 2005-11-30 | 2011-09-27 | Inotek Pharmaceuticals Corp | purine derivatives and methods of use of these |
US20070183995A1 (en) * | 2006-02-09 | 2007-08-09 | Conopco, Inc., D/B/A Unilever | Compounds useful as agonists of A2A adenosine receptors, cosmetic compositions with A2A agonists and a method for using the same |
GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
AR060607A1 (en) | 2006-04-21 | 2008-07-02 | Novartis Ag | PURINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION METHOD AND USES IN OBSTRUCTIVE OR INFLAMMATORY DISEASES OF RESPIRATORY ROADS. |
GB0607951D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
DE102006020349A1 (en) | 2006-04-28 | 2007-10-31 | Mahle International Gmbh | Piston engine and associated operating method |
US7691825B2 (en) * | 2006-06-06 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor agonists |
WO2008063712A1 (en) * | 2006-06-22 | 2008-05-29 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
EP1889846A1 (en) * | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
BRPI0716174A2 (en) * | 2006-09-01 | 2013-09-24 | Cv Therapeutics Inc | Methods and compositions for increasing patient tolerability during myocardial imaging methods. |
EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
US20080170990A1 (en) * | 2006-09-29 | 2008-07-17 | Cv Therapeutics, Inc. | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease |
CA2669108A1 (en) * | 2006-11-10 | 2008-05-15 | Novartis Ag | Cyclopentene diol monoacetate derivatives |
MX2009007071A (en) * | 2007-01-03 | 2009-10-13 | Cv Therapeutics Inc | Myocardial perfusion imaging. |
WO2008133129A1 (en) * | 2007-04-16 | 2008-11-06 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for glaucoma comprising adenosine a2a receptor agonist as active ingredient |
AU2007353780B2 (en) * | 2007-05-17 | 2013-11-14 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
RU2443708C2 (en) * | 2007-05-17 | 2012-02-27 | Си Ви Терапьютикс, Инк. | Method of producing a2a-adenosine receptor agonist and polymorphic modifications thereof |
US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
US8942112B2 (en) * | 2008-02-15 | 2015-01-27 | Cisco Technology, Inc. | System and method for providing selective mobility invocation in a network environment |
EP2300489B1 (en) | 2008-06-06 | 2015-11-11 | Harbor Therapeutics, Inc. | Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds |
CN102164591A (en) * | 2008-09-29 | 2011-08-24 | 吉利德科学股份有限公司 | Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods |
US7957314B2 (en) * | 2008-12-12 | 2011-06-07 | Cisco Technology, Inc. | System and method for provisioning charging and policy control in a network environment |
ES2613698T3 (en) | 2010-01-11 | 2017-05-25 | Inotek Pharmaceuticals Corporation | Combination, kit and method of intraocular pressure reduction |
JP2013523739A (en) | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | Method for reducing intraocular pressure in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof |
US20130109645A1 (en) | 2010-03-31 | 2013-05-02 | The united States of America,as represented by Secretary,Dept.,of Health and Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
US9215588B2 (en) | 2010-04-30 | 2015-12-15 | Cisco Technology, Inc. | System and method for providing selective bearer security in a network environment |
JP2011098990A (en) * | 2011-02-21 | 2011-05-19 | Gilead Palo Alto Inc | Myocardial perfusion imaging using adenosine receptor agonist |
WO2012149196A1 (en) | 2011-04-27 | 2012-11-01 | Reliable Biopharmaceutical Corporation | Improved processes for the preparation of regadenoson and a new crystalline form thereof |
CZ308577B6 (en) | 2011-08-18 | 2020-12-16 | Farmak, A. S. | Process for preparing 2- (4-methoxy carbonyl pyrazol-1-yl) adenosine and 2- (4-ethoxycarbonylpyrazol-1-yl) adenosine |
CZ304053B6 (en) | 2011-08-22 | 2013-09-04 | Farmak, A. S. | Process for preparing 2-[4-[(methylamino)carbonyl]-1-H-pyrazol-1-yl]adenosine monohydrate |
KR20140128974A (en) | 2012-01-26 | 2014-11-06 | 이노텍 파마슈티컬스 코포레이션 | Anhydrous polymorphs of ((2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) methyl nitrate and processes of preparation thereof |
WO2014083580A2 (en) * | 2012-11-30 | 2014-06-05 | Leiutis Pharmaceuticals Pvt. Ltd. | Pharmaceutical compositions of regadenoson |
EA201591433A1 (en) | 2013-03-15 | 2015-12-30 | Инотек Фармасьютикалс Корпорейшн | OPHTHALMIC COMPOSITIONS |
EP2789624B1 (en) | 2013-04-11 | 2020-09-23 | AMRI Italy S.r.l. | Stable solid forms of regadenoson |
CZ305213B6 (en) | 2013-04-29 | 2015-06-10 | Farmak, A. S. | Polymorph E, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]adenosine and process for its preparation |
WO2014207758A2 (en) | 2013-05-30 | 2014-12-31 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel polymorph of regadenoson |
CN104513241B (en) * | 2013-09-30 | 2017-02-08 | 浙江海正药业股份有限公司 | New regadenoson intermediate, preparation method and application thereof |
CN104744540A (en) * | 2013-12-26 | 2015-07-01 | 上海紫源制药有限公司 | Preparation method for regadenoson |
CN105085593A (en) * | 2014-04-21 | 2015-11-25 | 上海紫源制药有限公司 | Regadenoson crystal form and preparation method thereof |
WO2016126734A1 (en) | 2015-02-06 | 2016-08-11 | Apicore Us Llc | Process of making regadenoson and novel polymorph thereof |
US9809617B2 (en) | 2015-07-03 | 2017-11-07 | Shanghai Ziyuan Pharmaceutical Co., Ltd. | Crystal form of regadenoson and preparation method thereof |
CN106397442B (en) * | 2015-07-28 | 2020-03-27 | 国药集团国瑞药业有限公司 | Purification method of regadenoson |
KR20190095372A (en) | 2017-01-13 | 2019-08-14 | 토비시 파마슈티칼 컴패니 리미티드 | Neutrophil activation regulator |
WO2019191389A1 (en) | 2018-03-29 | 2019-10-03 | Johnson Matthey Public Limited Company | Solid-state forms of regadenoson, their use and preparation |
US10815265B2 (en) | 2018-06-29 | 2020-10-27 | Usv Private Limited | Process for preparation of regadenoson and polymorphs thereof |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK135130B (en) | 1970-12-28 | 1977-03-07 | Takeda Chemical Industries Ltd | Analogous process for the preparation of 2-substituted adenosine derivatives or acid addition salts thereof. |
BE787064A (en) | 1971-08-03 | 1973-02-01 | Philips Nv | MAGNETIC DEVICE CONTAINING DOMAINS |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
US4120947A (en) * | 1976-03-31 | 1978-10-17 | Cooper Laboratories, Inc. | Xanthine compounds and method of treating bronchospastic and allergic diseases |
SE7810946L (en) * | 1978-10-20 | 1980-04-21 | Draco Ab | METHOD OF TREATING CHRONIC OBSTRUCTIVE AIR DISEASE |
US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4593095A (en) * | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4696932A (en) * | 1984-10-26 | 1987-09-29 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active xanthine derivatives |
JPS6299395A (en) | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | 2-alkinyladenosine and antihypertensive |
US4968697A (en) * | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4990498A (en) * | 1988-04-26 | 1991-02-05 | Temple University-Of The Commonwealth System Of Higher Education | 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof |
US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5070877A (en) | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
DE3831430A1 (en) * | 1988-09-15 | 1990-03-22 | Bayer Ag | SUBSTITUTED 4-HETEROCYCLYLOXIMINO-PYRAZOLIN-5-ONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PEST CONTROL |
DE68916036T2 (en) | 1988-11-15 | 1994-09-29 | Yamasa Shoyu Kk | AGENT FOR TREATMENT AND PROPHYLAXIS OF CORONARY AND CEREBRAL ISCHEMIC DISEASES. |
IT1229195B (en) | 1989-03-10 | 1991-07-25 | Poli Ind Chimica Spa | XANTHINIC DERIVATIVES WITH BRONCODILATORY ACTIVITY AND THEIR THERAPEUTIC APPLICATIONS. |
WO1990015812A1 (en) | 1989-06-20 | 1990-12-27 | Yamasa Shoyu Kabushiki Kaisha | Intermediate for 2-alkynyladenosine synthesis, production of said intermediate, production of 2-alkynyladenosine from said intermediate, and stable 2-alkynyladenosine derivative |
US5032252A (en) * | 1990-04-27 | 1991-07-16 | Mobil Oil Corporation | Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator |
DE4019892A1 (en) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | New xanthine derivs. are selective A1 adenosine antagonists - useful for treating CNS disorders (e.g. senile dementia) and heart and circulation disorders |
US5189027A (en) | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
FR2671356B1 (en) | 1991-01-09 | 1993-04-30 | Inst Nat Sante Rech Med | METHOD FOR DESCRIBING ANTIBODY (AB) DIRECTORIES AND T CELL RECEPTORS (TCR) IN THE INDIVIDUAL'S IMMUNE SYSTEM. |
JP2740362B2 (en) | 1991-02-12 | 1998-04-15 | ヤマサ醤油株式会社 | Stable solid 2-octynyl adenosine and process for its preparation |
JP3053908B2 (en) | 1991-06-28 | 2000-06-19 | ヤマサ醤油株式会社 | 2-alkynyl adenosine derivatives |
US5516894A (en) * | 1992-03-11 | 1996-05-14 | The General Hospital Corporation | A2b -adenosine receptors |
IT1254915B (en) | 1992-04-24 | 1995-10-11 | Gloria Cristalli | ADENOSINE DERIVATIVES FOR ACTIVITY A2 AGONIST |
GB9210839D0 (en) | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
JPH08500967A (en) | 1992-06-12 | 1996-02-06 | ガーヴァン インスティチュート オブ メディカル リサーチ | DNA sequences encoding human A1, A2a and A2b adenosine receptors |
EP0601322A3 (en) | 1992-10-27 | 1994-10-12 | Nippon Zoki Pharmaceutical Co | Adenosindeaminase inhibitor. |
CA2112031A1 (en) * | 1992-12-24 | 1994-06-25 | Fumio Suzuki | Xanthine derivatives |
US5477857A (en) | 1993-09-10 | 1995-12-26 | Discovery Therapeutics, Inc. | Diagnostic uses of hydrazinoadenosines |
WO1995011681A1 (en) | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
WO1995023148A1 (en) * | 1994-02-23 | 1995-08-31 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivative |
US5704491A (en) * | 1995-07-21 | 1998-01-06 | Cummins-Allison Corp. | Method and apparatus for discriminating and counting documents |
US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
US6514949B1 (en) * | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
US6448235B1 (en) * | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
US5854081A (en) * | 1996-06-20 | 1998-12-29 | The University Of Patent Foundation | Stable expression of human A2B adenosine receptors, and assays employing the same |
US5780481A (en) * | 1996-08-08 | 1998-07-14 | Merck & Co., Inc. | Method for inhibiting activation of the human A3 adenosine receptor to treat asthma |
US5776960A (en) * | 1996-10-16 | 1998-07-07 | Buckman Laboratories International, Inc. | Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same |
US5770716A (en) | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
EP0983768A1 (en) | 1997-05-23 | 2000-03-08 | Nippon Shinyaku Co., Ltd. | Medicinal composition for prevention or treatment of hepatopathy |
JP2002505687A (en) | 1997-06-18 | 2002-02-19 | ディスカバリー セラピューティクス,インコーポレイテッド | Compositions and methods for preventing restenosis after a revascularization procedure |
US6026317A (en) | 1998-02-06 | 2000-02-15 | Baylor College Of Medicine | Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
CA2316994A1 (en) | 1998-06-08 | 1999-12-16 | Epigenesis Pharmaceuticals, Inc. | Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs |
US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
BR0013673A (en) | 1999-08-31 | 2002-05-28 | Univ Vanderbilt | Selective a2b adenosine receptor antagonists |
US6368573B1 (en) * | 1999-11-15 | 2002-04-09 | King Pharmaceuticals Research And Development, Inc. | Diagnostic uses of 2-substituted adenosine carboxamides |
US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
US6552023B2 (en) * | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
CA2671940A1 (en) * | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Identification of partial agonists of the a2a adenosine receptor |
US6387913B1 (en) * | 2000-12-07 | 2002-05-14 | S. Jamal Mustafa | Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists |
US6670334B2 (en) * | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
US6995148B2 (en) * | 2001-04-05 | 2006-02-07 | University Of Pittsburgh | Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy |
US6599283B1 (en) * | 2001-05-04 | 2003-07-29 | Cv Therapeutics, Inc. | Method of preventing reperfusion injury |
BR0209386A (en) * | 2001-05-14 | 2004-07-06 | Novartis Ag | Sulfonamide Derivatives |
US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
PL370207A1 (en) * | 2001-11-09 | 2005-05-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
KR20040068317A (en) * | 2001-12-20 | 2004-07-30 | 오에스아이 파마슈티컬스, 인코포레이티드 | Pyrimidine a2b selective antagonist compounds, their synthesis and use |
AU2003223497A1 (en) * | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
CN1646142A (en) | 2002-04-18 | 2005-07-27 | Cv医药有限公司 | Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
EP1524984A1 (en) | 2002-07-29 | 2005-04-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
JP4818127B2 (en) | 2004-01-27 | 2011-11-16 | ギリアード・パロ・アルト・インコーポレイテッド | Myocardial perfusion imaging method using adenosine receptor agonist |
JP2008516969A (en) * | 2004-10-15 | 2008-05-22 | シーブイ・セラピューティクス・インコーポレイテッド | Methods of preventing and treating airway remodeling and lung inflammation using A2B adenosine receptor antagonists |
CN101076343A (en) * | 2004-10-20 | 2007-11-21 | Cv医药有限公司 | Use of A2A adenosine receptor agonists |
CA2594328A1 (en) * | 2005-01-12 | 2006-07-20 | Richard J. Barrett | Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm |
NZ570239A (en) | 2006-02-03 | 2011-09-30 | Gilead Palo Alto Inc | Preparation of (1-{ 9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl} pyrazol-4-yl)-N-methylcarboxamide monohydrate |
WO2008063712A1 (en) | 2006-06-22 | 2008-05-29 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
BRPI0716174A2 (en) | 2006-09-01 | 2013-09-24 | Cv Therapeutics Inc | Methods and compositions for increasing patient tolerability during myocardial imaging methods. |
US20080170990A1 (en) * | 2006-09-29 | 2008-07-17 | Cv Therapeutics, Inc. | Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease |
MX2009007071A (en) * | 2007-01-03 | 2009-10-13 | Cv Therapeutics Inc | Myocardial perfusion imaging. |
AU2007353780B2 (en) | 2007-05-17 | 2013-11-14 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
WO2009076580A2 (en) | 2007-12-12 | 2009-06-18 | Thomas Jefferson University | Compositions and methods for the treatment and prevention of cardiovascular diseases |
CN102164591A (en) | 2008-09-29 | 2011-08-24 | 吉利德科学股份有限公司 | Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods |
-
1999
- 1999-06-22 US US09/338,185 patent/US6403567B1/en not_active Expired - Lifetime
-
2000
- 2000-06-21 JP JP2001515876A patent/JP4727880B2/en not_active Expired - Lifetime
- 2000-06-21 US US10/018,446 patent/US6642210B1/en not_active Ceased
- 2000-06-21 NZ NZ516334A patent/NZ516334A/en not_active IP Right Cessation
- 2000-06-21 DE DE60007127T patent/DE60007127T2/en not_active Expired - Lifetime
- 2000-06-21 BR BRPI0011856A patent/BRPI0011856B8/en not_active IP Right Cessation
- 2000-06-21 TR TR2002/00588T patent/TR200200588T2/en unknown
- 2000-06-21 KR KR10-2001-7016488A patent/KR100463300B1/en active IP Right Grant
- 2000-06-21 CN CNB008094594A patent/CN1167709C/en not_active Expired - Lifetime
- 2000-06-21 AT AT00960112T patent/ATE256141T1/en active
- 2000-06-21 WO PCT/US2000/040281 patent/WO2000078779A2/en active IP Right Grant
- 2000-06-21 PT PT00960112T patent/PT1189916E/en unknown
- 2000-06-21 IL IL14719800A patent/IL147198A0/en active IP Right Grant
- 2000-06-21 ES ES00960112T patent/ES2209974T3/en not_active Expired - Lifetime
- 2000-06-21 DK DK00960112T patent/DK1189916T3/en active
- 2000-06-21 CA CA002377746A patent/CA2377746C/en not_active Expired - Lifetime
- 2000-06-21 AU AU71324/00A patent/AU760806B2/en not_active Expired
- 2000-06-21 MX MXPA01013325A patent/MXPA01013325A/en active IP Right Grant
- 2000-06-21 DE DE122011000010C patent/DE122011000010I1/en active Pending
- 2000-06-21 EP EP00960112A patent/EP1189916B1/en not_active Expired - Lifetime
- 2000-06-22 AR ARP000103123A patent/AR024441A1/en active IP Right Grant
- 2000-09-13 TW TW089112272A patent/TWI230161B/en not_active IP Right Cessation
-
2001
- 2001-12-19 IL IL147198A patent/IL147198A/en unknown
- 2001-12-21 NO NO20016350A patent/NO322457B1/en not_active IP Right Cessation
-
2002
- 2002-01-14 ZA ZA200200301A patent/ZA200200301B/en unknown
- 2002-09-04 HK HK02106507.1A patent/HK1044952B/en not_active IP Right Cessation
-
2003
- 2003-08-29 US US10/652,378 patent/US7183264B2/en not_active Expired - Lifetime
-
2005
- 2005-10-18 US US11/252,760 patent/US7144872B2/en not_active Expired - Lifetime
-
2006
- 2006-10-27 US US11/588,834 patent/US7655637B2/en not_active Expired - Fee Related
-
2009
- 2009-12-14 US US12/637,311 patent/US20100160620A1/en not_active Abandoned
-
2010
- 2010-12-14 US US12/968,110 patent/US8278435B2/en not_active Expired - Fee Related
-
2011
- 2011-01-31 LU LU91785C patent/LU91785I2/en unknown
- 2011-02-03 BE BE2011C004C patent/BE2011C004I2/fr unknown
- 2011-02-07 FR FR11C0004C patent/FR11C0004I2/en active Active
- 2011-02-09 NO NO2011002C patent/NO2011002I2/en unknown
- 2011-02-16 CY CY2011002C patent/CY2011002I2/en unknown
-
2012
- 2012-08-29 US US13/598,451 patent/US8569260B2/en not_active Expired - Fee Related
-
2013
- 2013-09-06 US US14/020,736 patent/US9045519B2/en not_active Expired - Fee Related
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8278435B2 (en) | 1999-06-22 | 2012-10-02 | Gilead Sciences, Inc. | N-pyrazole A2A receptor agonists |
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
US9045519B2 (en) | 1999-06-22 | 2015-06-02 | Gilead Sciences, Inc. | N-pyrazole A2A receptor agonists |
US8569260B2 (en) | 1999-06-22 | 2013-10-29 | Gilead Sciences, Inc. | N-pyrazole A2A receptor agonists |
US9163057B2 (en) | 2000-02-23 | 2015-10-20 | Gilead Sciences, Inc. | Methods of myocardial perfusion imaging |
US8071566B2 (en) | 2000-02-23 | 2011-12-06 | Gilead Sciences, Inc. | Methods of coronary imaging |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
US8183226B2 (en) | 2002-07-29 | 2012-05-22 | Gilead Sciences, Inc. | Myocardial perfusion imaging method |
US8906878B2 (en) | 2002-07-29 | 2014-12-09 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
US8133879B2 (en) | 2002-07-29 | 2012-03-13 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
US9289446B2 (en) | 2002-07-29 | 2016-03-22 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
US8268988B2 (en) | 2006-02-03 | 2012-09-18 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
US8524883B2 (en) | 2006-02-03 | 2013-09-03 | Gilead Sciences, Inc. | Monohydrate of (1-{9-[4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide |
US9085601B2 (en) | 2006-02-03 | 2015-07-21 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
USRE47301E1 (en) | 2006-02-03 | 2019-03-19 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
US8106183B2 (en) | 2006-02-03 | 2012-01-31 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2377746A1 (en) | N-pyrazole a2a receptor agonists | |
CA2375430A1 (en) | C-pyrazole a2a receptor agonists | |
CA2375385A1 (en) | Propargyl phenyl ether a2a receptor agonists | |
CA2387533A1 (en) | Purine derivatives | |
CA2387531A1 (en) | Purine derivatives | |
BG106289A (en) | Purine derivatives | |
AU4613999A (en) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | |
WO1999038877A3 (en) | 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | |
AU2047300A (en) | Methods and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion | |
YU29099A (en) | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives | |
CA2411008A1 (en) | Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione | |
CA2040982A1 (en) | N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, their preparation and use | |
CA2361614A1 (en) | Compositions for treating inflammatory response | |
CA2373410A1 (en) | A2a receptor agonists | |
CA2072233A1 (en) | Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them | |
IL132599A0 (en) | Substituted 3,3-diamino-2-propenenitriles their preparation and use | |
CA2219359A1 (en) | Hydantoin derivatives as intermediates for pharmaceutical active compounds | |
CA2412594A1 (en) | Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives | |
PL343720A1 (en) | Novel octahydro-6,10-dioxo-6h-pyridazino/1,2-a/ /1,2/diazepin-1-carboxylic acid derivatives, preparation method and use for preparing therapeutically active compounds | |
AU5067696A (en) | Antiarrhythmic and cardioprotective substituted indenoylguanidines | |
HUT46214A (en) | Process for producing medical preparation suitable for treatment of peptic ulcer | |
CA2208630A1 (en) | 4-amino-2-ureidopyrimidine-5-carboxamides, processes for their preparation, pharmaceuticals comprising these compounds, and their use | |
PH24526A (en) | Novel imidazo and triazolothiadiazines and medicaments containing same | |
CA2182105A1 (en) | Chloropyrimide intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |